King Pharmaceuticals Provides Update on Embeda NDA Review

Dec 31, 2008 - King Pharmaceuticals, Inc. (NYSE: KG) today announced that the U.S. Food and Drug Administration (FDA) is continuing its review of the New Drug Application (NDA) for EMBEDA™ (morphine sulfate and naltrexone hydrochloride) extended release capsules.